Columbia University
Mitochondrial membrane potential disruptor compounds attenuate Lv1 activity
Published in Health Business Week, January 14th, 2005
"Human immunodeficiency virus type 1 (HIV-1) cDNA synthesis is inhibited in cells from some nonhuman primates by an activity called Lv1. Sensitivity to restriction by Lv1 maps to a region of the HIV-1 CA required for interaction with the cellular protein cyclophilin A.
"A similar antiviral activity in mammalian cells, Ref1, inhibits reverse transcription of marine leukemia virus (MLV), but only with viral strains bearing N-tropic CA," scientists in the United States report.
"Disruption of the HIV-1 CA-cyclophilin A interaction inhibits Lv1 restriction in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2005-01-14)
More Articles from Health Business Week
- Alliance Imaging, Inc.
Imaging services company commences proposed private offering - Amedica Corporation
Orthopedic device maker raises $6M in series B financing - Amphora Discovery Corporation
Drug discovery company completes $20M Series C financing - ArthroCare Corp.
Device firm appoints VP of finance and administration - Biopure Corporation
Oxygen therapeutics firm reports loss of $0.16 per share - Blue Cross and Blue Shield of Minnesota
New $1.00 tobacco tax proposal may reduce smoking, save lives - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
